featured
Fecal Microbiota Alterations Associated With Response to Infliximab Therapy in Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Inflammatory Bowel Diseases
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn's Disease
Inflamm. Bowel Dis. 2020 Oct 23;26(11)1636-1647, X Zhuang, Z Tian, R Feng, M Li, T Li, G Zhou, Y Qiu, B Chen, Y He, M Chen, Z Zeng, S ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.